Crescendo Biologics’ Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors View PDF

Crescendo Biologics Recognised at OBN Annual Awards Dinner View PDF

EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics’ Series A Financing View PDF

Crescendo Biologics Wins Cambridge Business Innovation Award View PDF